Why Many FGF23-Secreting Tumors Are Hidden in Sinuses or Mandible: Specialist Next Steps

Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare disorder marked by bone pain, muscle weakness, and fractures. At its core is excess fibroblast growth factor 23 (FGF23), a hormone that drives phosphate loss through the kidneys. Many of these FGF23-secreting tumors arise in the head and neck region—particularly in the sinuses or mandible—making them difficult to locate and treat. Understanding why these tumors hide in such locations and knowing the specialist next steps can speed up diagnosis and improve outcomes.

Why Head and Neck Locations Are Common

Oncogenic osteomalacia head and neck tumor location studies show that up to 40% of FGF23-secreting mesenchymal tumors are found in the facial skeleton or paranasal sinuses. Several factors contribute:

• Embryologic origins
  The sinuses and mandible develop from mesenchymal tissue capable of giving rise to phosphaturic mesenchymal tumors.
• Rich vascular supply
  High blood flow in these areas can nourish small tumors and help them grow undetected.
• Complex anatomy
  Multiple air cells, bony compartments, and overlapping structures make routine imaging less sensitive.
• Slow growth
  These tumors often enlarge very slowly, delaying the appearance of symptoms linked directly to their mass effect.

Clinical Clues to Suspect TIO

Patients with oncogenic osteomalacia often present with nonspecific complaints:

• Bone aches and muscle weakness that worsen over months or years
• Recurrent low-impact fractures (e.g., ribs, femur)
• Difficulty walking, rising from a chair, or climbing stairs
• Laboratory findings:
  • Low serum phosphate (hypophosphatemia)
  • High alkaline phosphatase
  • Normal calcium levels
  • Elevated or inappropriately normal FGF23

Because these signs overlap with osteoporosis or vitamin D deficiency, TIO may be overlooked unless clinicians recognize the phosphate wasting pattern.

Why Tumors Hide in Sinuses or Mandible

1. Small size
   Many FGF23-secreting tumors are under 2 cm, making them less obvious on routine X-rays or CT scans.
2. Deep location
   The paranasal sinuses and mandibular bone sit behind layers of soft tissue, mucosa, or teeth—areas not routinely imaged in metabolic bone disease workups.
3. Variable imaging appearance
   These tumors can mimic benign lesions such as ossifying fibroma, hemangioma, or fibrous dysplasia.
4. Lack of local symptoms
   Sinus tumors often don’t cause nasal obstruction or pain until they reach a larger size. Mandibular lesions may not affect chewing or tooth alignment at first.

Specialist Next Steps: Advanced Localization

Once clinical suspicion is high and blood tests confirm phosphate wasting with elevated FGF23, the goal shifts to precise localization. Specialists typically take a stepwise approach:

1. Comprehensive imaging
   • Ga-68 DOTATATE PET/CT: High sensitivity for somatostatin-receptor–positive mesenchymal tumors
   • 18F-FDG PET/CT: Useful if DOTATATE study is negative or unavailable
   • MRI of the skull base and mandible with contrast: Excellent soft-tissue resolution
   • CT of paranasal sinuses and mandible: Bone detail helps when MRI is equivocal
2. Selective venous sampling
   • Catheter-directed sampling of venous drainage from suspected regions (e.g., jugular veins, facial veins)
   • Measures FGF23 gradient to narrow down the tumor’s location
3. Endoscopic evaluation
   • If imaging suggests a sinus lesion, ENT specialists perform nasal endoscopy to visualize or biopsy the mass
   • Dental and maxillofacial evaluation for mandibular lesions

Treatment Planning

Once the tumor is localized, multidisciplinary teams (endocrinology, radiology, ENT, oral surgery, neurosurgery) collaborate on:

• Surgical resection
  Complete removal is the only definitive cure. Even small residual tissue can continue secreting FGF23.
• Reconstruction and rehabilitation
  Mandibular lesions may require bone grafting or dental prostheses. Sinus resections may involve flap reconstruction or stenting.
• Post-operative monitoring
  Frequent checks of phosphate levels and FGF23 for early detection of recurrence.

When Surgery Is Not Immediately Feasible

In rare cases where the tumor cannot be safely accessed or fully removed:

• Medical management
  • Phosphate supplements divided throughout the day
  • Active vitamin D analogs (calcitriol or alfacalcidol)
  • Burosumab (anti-FGF23 monoclonal antibody) under specialist guidance
• Radiation therapy
  Considered for unresectable or residual tumors, though data are limited.
• Ongoing imaging
  Repeated DOTATATE PET/CT or MRI every 6–12 months until a resectable lesion is found.

Tips for Patients and Clinicians

• Keep detailed symptom journals: track pain, weakness, and any sinus or jaw discomfort.
• Share all previous imaging and reports—small findings may gain importance in the context of TIO.
• Coordinate care through a metabolic bone disease center or a specialized TIO clinic.

If you’re experiencing unexplained bone pain, weakness, or repeated fractures, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker(https://ubiehealth.com/) to gather questions before seeing a specialist.

Moving Forward: Speak to a Doctor

Oncogenic osteomalacia can be challenging to diagnose and treat, but with modern imaging, biochemical tests, and multidisciplinary care, most patients achieve full recovery after tumor removal. If you suspect you or a loved one may have TIO—or if you have any serious or worsening symptoms—please speak to a doctor promptly. Early action can prevent fractures, restore strength, and improve quality of life.